Slide 1: FY 2011 Results Conference Call
FY 2011 Results Conference Call March 9th, 2012
Slide 2: FY 2011 Results Highlights
FY 2011 RESULTS HIGHLIGHTS Revenues improvement, despite H2’11 weakness and negative exchange rate impact Revenues: +8.8% FY’11 vs. FY’10 +10.4% at current exchange rates Significant Operating Results improvement EBITDA: +13.7% FY’11 vs. FY’10 EBIT: +12.2% FY’11 vs. FY’10 Significant Net Earni
Slide 3: FY'11 Results: Income Statement
FY’11 RESULTS: INCOME STATEMENT Full Year Change €/mln 2011 2010 Amount % Net Revenues 440.0 404.5 +35.5 +8.8% Gross profit 313.9 284.7 +29.1 +10.2% Gross margin 71.3% 70.4% S&M (78.0) (69.8) (8.2) +11.7% R&D (21.5) (19.3) (2.1) +11.1% G&A (45.9) (41.7) (4.2) +10.2% Total operating expenses (145.4)
Slide 4: Revenues Breakdown: By Technology
REVENUES BREAKDOWN: BY TECHNOLOGY CLIA sales still growing although challenging 2H’11 macroeconomic environment Sales: +10.9% FY’11 vs. FY’10 % on Revenues: 73.7% FY’11 vs. 69.9% FY’10 Due to: Vitamin D +10.6% FY’11 vs. FY’10 CLIA ex Vitamin D +11.2% FY’11 vs. FY’10 ELISA sales (net of Murex bus
Slide 5: Revenues Breakdown: By Geography
REVENUES BREAKDOWN: BY GEOGRAPHY Change Amounts in millions of euros 2011 2010 Amount % % at CER Europe and Africa 188.1 178.0 +10.1 +5.7% +5.6% Central and South America 30.5 25.4 +5.1 +20.1% +20.8% Asia Pacific 42.2 32.9 +9.3 +28.1% +26.5% North America 140.6 145.2 -4.6 -3.2% +1.7% Total w ithout
Slide 6: 2011 Installed Base Enlargement
2011 INSTALLED BASE ENLARGEMENT Total LIAISON systems installed: 4,206* units at the end of 2011 (3,641 units at December 31, 2010) Total LIAISON systems new placements: 565* units installed in FY’11 +437 LIAISON units +128* LIAISON XL units: successful soft launch in Europe, Israel and Australi
Slide 7: Profitability Profile
PROFITABILITY PROFILE Profitability and Net Result improvement, despite weakness in revenues and negative exchange rate impact FY’11 vs. FY’10 % on Tot Sales Gross Profit +10.2% 71.3% (from 70.4%) EBITDA +13.7% 43.2% (from 41.3%) EBIT +12.2% 37.1% (from 36.0%) Net results improved notwithstanding no
Slide 8: FY'11 Results: Balance Sheet
FY’11 RESULTS: BALANCE SHEET €/mln 12/31/2011 12/31/2010 Total intangible assets 121.9 126.9 Total tangible assets 62.7 57.6 Other non-current assets 20.7 20.2 Net Working Capital 133.9 106.4 Other non-current liabilities (29.7) (28.2) Net Capital Employed 309.5 282.9 Net Financial Position 41.6 33.
Slide 9: Solid Financial Structure
SOLID FINANCIAL STRUCTURE CASH FLOW STATEMENT Change in €/mln 12/31/2011 12/31/2010 value Operating activities 108.6 95.8 +12.8 Investing activities (27.5) (73.4) +45.9 Financing activities (79.3) (7.9) -71.4 Net change in cash and cash equivalents 1.8 14.5 -12.8 Cash and cash equivalents at the end
Slide 10: Board of Directors' Proposals
BOARD OF DIRECTORS’ PROPOSALS The Board of Directors agreed to submit a motion to the Shareholders’ Meeting convened for April 23, 2012, on the first calling, and April 24, 2012, on the second calling, recommending: • the approval of the annual financial statements at December 31, 2011; • the approp
Slide 11: FY 2012 Guidelines
FY 2012 GUIDELINES In view of the Group’s operating performance after December 31, 2011 and taking into account possible evolutions of the global macroeconomic scenario and the diagnostic sector in particular, the management believes that in 2012 DiaSorin will report: Revenues in line with 2011 or
Slide 12: FY 2012 Pipeline
FY 2012 PIPELINE 2012 1Q 2Q 3Q 4Q Hormonology Aldosterone IMMUNODIAGNOSTICS H pylori GI Stool Testing GDH Measles IgM Infectious Diseases Mumps IgM HTLV I/II PARVO CMV EBV VZV MOLECULAR DIAGNOSTICS Infectious Diseases TOXO BKV HSV 1-2 CML (BCR-ABL p210) CML (BCR-ABL p190) Onco Hematology APL (PML-RA
Slide 13: 2012 US Menu Expansion
2012 US MENU EXPANSION 2012 1Q 2Q 3Q 4Q C-peptide IGF -I fT4 fT3 Anti-TPO FSH Hormonology LH IMMUNODIAGNOSTICS Prolactin HCG Estradiol II Progesterone II Testosterone Renin Hypertension Aldosterone HSV M + cntr Infectious Diseases Rubella M Conference call FY 2011 Mar 9, 2012 12